Abstract: Provided herein are oligomeric compounds comprising a modified oligonucleotide and a conjugate group for modulating the amount or activity of a target nucleic acid in extra hepatic tissues and extra hepatic cells. Also provided herein are methods of modulating the amount or activity of an extra-hepatic nucleic acid target in a cell comprising contacting the cell with the oligomeric compound or antisense compound.
Type:
Application
Filed:
September 26, 2016
Publication date:
February 25, 2021
Applicant:
Ionis Pharmaceuticals, Inc.
Inventors:
Thazha P. Prakash, Richard Lee, Punit P. Seth, Eric E. Swayze, Frank Rigo, Michael Oestergaard
Abstract: The disclosure provides a selective inhibitor of DNA-binding to poly (ADP-ribose) polymerase 1 (PARP1), or a pharmaceutically acceptable salt or solvate thereof, for use in treating, ameliorating or preventing cancer. The treatment may be given to a subject suffering from or at risk of osteoporosis or a subject requiring a long-term therapy.
Type:
Application
Filed:
January 16, 2019
Publication date:
February 25, 2021
Inventors:
Melinda DUER, David REID, Uliana BASHTANOVA
Abstract: The present application provides: a technique for promoting hyaluronic acid synthesis by hyaluronic acid-producing cells; a method for evaluating the responsiveness of hyaluronic acid-producing cells to a compound; or a method for evaluating the responsiveness of a polysaccharide derivative represented by formula 1 in the description or a salt thereof to hyaluronic acid-producing cells. By bringing a polysaccharide derivative represented by formula 1 in the description or a salt thereof into contact with hyaluronic acid-producing cells, promotion of hyaluronic acid synthesis is achieved in the hyaluronic acid-producing cells. Further, by using the polysaccharide derivative or a salt thereof for hyaluronic acid-producing cells, the responsiveness of the hyaluronic acid-producing cells can be evaluated using the production of hyaluronic acid as an index.
Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
Abstract: Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.
Type:
Application
Filed:
August 9, 2019
Publication date:
February 25, 2021
Applicant:
University of British Columbia
Inventors:
Jayachandran N. Kizhakkedathu, Rajesh A. Shenoi, Cedric J. Carter, Donald E. Brooks
Abstract: The invention relates to a food supplement containing minerals and/or vitamins, a humectant and, for example, essential oils. The food supplement is formulated as an oral spray. In particular, the invention relates to a concentrated food supplement in the form of an oral spray, containing a combination of magnesium ions, panthenol (vitamin B5), caffeine, menthol aroma and/or peppermint aroma, and a humectant. The food supplement is particularly suited for use in sport and in stressful situations.
Abstract: The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.
Type:
Application
Filed:
May 3, 2019
Publication date:
February 25, 2021
Applicants:
CONSIGLI NAZIONALE DELLE RICERCHE, FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, UNIVERSITA DEGLI STUDI DI GENOVA
Inventors:
Markus BARTHEL, Marco CASSANI, Mariangela FIGINI, Juan GRANJA, Teresa PELLEGRINO, Alessandra QUARTA
Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred.
Type:
Application
Filed:
October 9, 2019
Publication date:
February 25, 2021
Applicant:
Clene Nanomedicine, Inc.
Inventors:
David Kyle Pierce, Mark G. Mortenson, David A. Bryce
Abstract: Compositions and methods for ablating CD206 expressing macrophages and/or CD206 expressing myeloid derived suppressor cells (MDSCs) are disclosed. In certain aspects, disclosed methods comprise administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties and one or more therapeutic agents attached thereto. In certain aspects, the therapeutic agent comprises a metal. In further aspects, the therapeutic agent comprises a cytotoxic agent.
Abstract: The present invention describes new formulations of semiochemical compounds for mammals in wick diffusers particularly effective in controlling the diffusion of several semiochemicals having different volatilities over long periods of time and independently of the temperature and humidity conditions.
Abstract: A method for treating inflammatory diseases is provided. The method may include administering to a subject in need thereof a therapeutically effective amount of isolated extracellular vesicles or exosomes obtained from mesenchymal stem cells pre-conditioned with at least TNF-?. The isolated extracellular vesicles or exosomes may exhibit (a) enhanced expression of flotillin-1, (b) enhanced expression of CD73, or (c) enhanced expression of IDO. A method of isolating extracellular vesicles or exosomes capable of treating an inflammatory disease is also provided, wherein the method may include (a) culturing stem cells in a growth medium, (b) then culturing the stem cells in a starve medium supplemented with at least TNF-?, and (c) separating exosomes or extracellular vesicles from the culture. Cultures suitable for treatment are also provided.
Abstract: Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer.
Type:
Application
Filed:
December 3, 2018
Publication date:
February 25, 2021
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Abstract: Described herein are macrophages or macrophage precursor cells lacking functional expression of MHC genes. The macrophages may express HLA-G or a modified MHC gene that does not elicit an immune response in an allogeneic subject but remains recognized by NK cells. The cells may further comprise a chimeric antigen receptor.
Abstract: Disclosed is a method for treating glioblastoma or other brain tumors. The method includes steps of preparing cells comprising a chimeric antigen receptor (CAR) molecule and administering to a mammal in need thereof an effective amount of the prepared cells. Also disclosed is that the CAR molecule contains an antigen binding domain that binds to the tumor antigen associated with the glioblastoma or other brain tumors, and the tumor antigen is carbonic anhydrase IX.
Abstract: Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.
Type:
Application
Filed:
December 28, 2018
Publication date:
February 25, 2021
Inventors:
Harold David Gunn, David W. Mullins, Mark Bazett, Shirin Kalyan
Abstract: The present invention provides a lipid nanoparticle containing the following (a) to (c): (a) a nucleic acid encoding a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR); (b) a cationic lipid; and (c) a non-cationic lipid. The present invention also provides a CAR- or exogenous TCR-zo expressing immunocyte obtained by introducing the lipid nanoparticle into in vivo or ex vivo T cells, and an in vivo or ex vivo therapeutic approach using the immunocytes for disease such as cancer and the like.
Abstract: Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
Type:
Application
Filed:
February 7, 2019
Publication date:
February 25, 2021
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Abstract: The present invention generally relates to methods of preparing leukocytes, particularly T cells, ex vivo for use in immunotherapy, particularly cancer immunotherapy. More specifically, the invention relates to methods for the preparation of leukocytes exhibiting cytotoxic properties for use in adoptive cell transfer. The invention also relates to cells and compositions including them for cancer immunotherapy. The invention also relates to methods of immunotherapy, particularly cancer immunotherapy. The present invention relates to a method for producing a leukocyte that has an enhanced capacity for killing a target cell, the method including contacting the leukocyte with a PTPN2 inhibitor in conditions for enabling the inhibitor to inactivate PTPN2 in the leukocyte, thereby producing a leukocyte that has an enhanced capacity for killing a target cell. Preferably, the leukocyte is contacted with the PTPN2 inhibitor in the absence of a T helper cell.
Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
Type:
Application
Filed:
September 9, 2020
Publication date:
February 25, 2021
Inventors:
Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
Type:
Application
Filed:
September 9, 2020
Publication date:
February 25, 2021
Applicant:
Precision BioSciences, Inc.
Inventors:
Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
November 4, 2020
Publication date:
February 25, 2021
Inventors:
Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
November 4, 2020
Publication date:
February 25, 2021
Inventors:
Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
November 4, 2020
Publication date:
February 25, 2021
Inventors:
Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
November 4, 2020
Publication date:
February 25, 2021
Inventors:
Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
Type:
Application
Filed:
September 1, 2020
Publication date:
February 25, 2021
Inventors:
Brian C. TURNER, Yosef REFAELI, Gregory A. BIRD
Abstract: The present application provides methods and processes for making and using a mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the mesenchymal stem cell secretome described herein.
Abstract: The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.
Type:
Application
Filed:
June 4, 2020
Publication date:
February 25, 2021
Applicant:
Spiritus Therapeutics, Inc.
Inventors:
Marilyn Glassberg Csete, Sharon Elliot, Robin Smith
Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.
Type:
Application
Filed:
February 7, 2019
Publication date:
February 25, 2021
Inventors:
Yong-Soo CHOI, Jung Uk HWANG, Kyuboem HAN, Chun-Hyung KIM
Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and a replication-competent oncolytic virus such as conditionally replication-competent chimeric orthopoxvirus (CF33). The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
Type:
Application
Filed:
April 30, 2019
Publication date:
February 25, 2021
Inventors:
Alexandra J. ANNALA, Karen S. ABOODY, Yuman FONG, Nanhai G. CHEN, Mohamed HAMMAD, Rachael MOONEY, Jennifer COVELLO
Abstract: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.
Type:
Application
Filed:
November 9, 2020
Publication date:
February 25, 2021
Applicant:
Kolon TissueGene, Inc.
Inventors:
Moon Jong Noh, Hyun Bae, Sung Woo Kang, Kwan Hee Lee
Abstract: Methods for treating cardiovascular disorders that include administration of an ECM based composition to damaged cardiovascular tissue in conjunction with a treatment remedy, such as transmyocardial revascularization (TMR), which induces enhanced bioremodeling of the damaged cardiovascular tissue and regeneration of new cardiovascular tissue and associated structures with site-specific structural and functional properties.
Abstract: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.
Type:
Application
Filed:
November 9, 2020
Publication date:
February 25, 2021
Inventors:
Moon Jong NOH, Hyun BAE, Sung Woo KANG, Kwan Hee LEE
Abstract: The current invention provides for methods and systems of inducing cell cycle exit and terminal differentiation in stem cells undergoing differentiation into various mature cell types in particular pancreatic endocrine cells. The current invention also provides for methods and systems of inducing differentiation of pancreatic endocrine cells from stem cells. The invention also provides for the cells produced by the methods that are suitable for transplantation or grafting into a subject for the prevention and/or treatment of disease, and useful for basic research and drug testing.
Abstract: The disclosure provides a composition for inhibiting thrombosis. The composition includes 5 to 25% by weight of Fish Oil, 15 to 55% by weight of Willow Bark Extract, and 0.2 to 5% by weight of Vitamin E.
Type:
Application
Filed:
November 6, 2020
Publication date:
February 25, 2021
Applicant:
P Tech, LLC
Inventors:
Peter M. Bonutti, Justin E. Beyers, Tonya M. Bierman
Abstract: Provided is a method for producing a composition containing plasmalogen derived from a plasmalogen-containing animal tissue, the method being without significantly decreasing an amount of plasmalogen derived the plasmalogen-containing animal tissue. A method for producing a composition containing plasmalogen derived from an animal tissue, the method comprising: (A) concentrating an alcohol extract of a plasmalogen-containing animal tissue, and (B) after diluting a concentrated product obtained by (A), allowing to stand under refrigeration.
Abstract: A honey based composition is described. The composition includes a mixture of honey, a short chain fatty alcohol and a fatty ester or wax. The composition has applications for use in wound dressings and in one embodiment may be a gel. The composition has a higher than expected storage stability, remaining stable for many weeks when held at elevated temperatures and retains all of the other desirable characteristics including anti-microbial activity.
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate-degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
Type:
Application
Filed:
September 2, 2020
Publication date:
February 25, 2021
Applicant:
OXTHERA INTELLECTUAL PROPERTY AB
Inventors:
Elisabeth LINDNER, Maria ÅKERMAN, Anna SJÖGREN, Orla MCCALLION
Abstract: The invention provides a composition comprising a bacterial strain of the genus Megasphaera, for use in stimulating the immune system in subject.
Type:
Application
Filed:
September 4, 2020
Publication date:
February 25, 2021
Inventors:
Imke Elisabeth MULDER, Parthena FOTIADOU, Amy Beth HOLT, Suaad AHMED, Anna ETTORRE, Samantha YUILLE, Ted DINAN, John CRYAN
Abstract: Methods of treating neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof by administering ammonia oxidizing microorganisms are disclosed. Preparations for treating disorders, including neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof including ammonia oxidizing microorganisms are disclosed. Kits including ammonia oxidizing microorganism preparations and devices for administering ammonia oxidizing preparations are provided.
Type:
Application
Filed:
March 28, 2019
Publication date:
February 25, 2021
Inventors:
David R. Whitlock, Todd Krueger, Lauren Nicole Ambrogio
Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
Abstract: The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.
Type:
Application
Filed:
September 28, 2018
Publication date:
February 25, 2021
Inventors:
Gwangpyo KO, Boram SEO, Woon Ki KIM, Kyungchan JEON
Abstract: Provided are vesicles derived from bacteria of the genus Lactococcus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in samples obtained from patients with diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease and depression, compared with a normal individual, and the vesicles inhibited the secretion of inflammation mediators caused by pathogenic vesicles. Therefore, it is expected that the vesicles derived from bacteria of the genus Lactococcus can be effectively used for a method of diagnosing diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease or depression, and a composition for preventing or treating the disease or inflammatory disease.
Type:
Application
Filed:
February 1, 2019
Publication date:
February 25, 2021
Applicants:
MD HEALTHCARE INC., AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Abstract: An isolated lactic acid bacterium strain or fermentation metabolite thereof has an anti-oxidant function and is in form of a food composition or a pharmaceutical composition, wherein the isolated lactic acid bacterium strain comprises at least one of an OLP-01 strain of Bifidobacterium longum subsp. longum; a Bv-889 strain of Bifidobacterium breve; a BLI-02 strain of Bifidobacterium longum subsp. infantis; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a GL-104 strain of Lactobacillus reuteri; an AP-32 strain of Lactobacillus salivarius subsp. salicinius; and a bv-77 strain of Lactobacillus rhamnosus.
Type:
Application
Filed:
July 28, 2020
Publication date:
February 25, 2021
Inventors:
PEI-SHAN HSIEH, CHUNG-WEI KUO, YI-CHUN TSAI, HSIEH-HSUN HO, YI WEI KUO, JIA-HUNG LIN
Abstract: Provided is a composition comprising an isolated Lactobacillus paracasei D3.5 strain or cellular components thereof. In some embodiments, the composition is provided in a pharmaceutically acceptable carrier, which may be a food product, tablet or capsule suitable for enteral administration, etc. Also provided is a composition comprising lipoteichoic acid isolated from Lactobacillus paracasei D3.5 strain, which may be provided in a pharmaceutically acceptable carrier.
Abstract: The present invention refers to a composition containing a) a fermented supernatant, or fractions thereof, of Lactobacillus casei or paracasei species, the species being characterized by having in their DNA genome at least one DNA sequence essentially identical to one of the sequence selected from the group consisting of: SEQ ID No 1 to 5, and b) proper carriers and/or diluents and/or excipients. The fermented supernatant is obtainable through a method characterized by the fermentation of the Lactobacillus casei or paracasei species in a minimum solution additioned with prebiotic fibers. The fermented supernatant does not have prebiotic fibers.
Type:
Application
Filed:
February 4, 2019
Publication date:
February 25, 2021
Applicant:
POSTBIOTiCA S.R.L.
Inventors:
Maria RESCIGNO, Giuseppe PENNA, Francesca ALGIERI
Abstract: The present disclosure pertains to a treatment strategy to combat select bacteria in the gut, such as H. pylori. The strategy uses a probiotic-based system to express and deliver a guided antimicrobial peptide to the gut. The guided antimicrobial peptide is expressed from a hybrid gene that codes for an antimicrobial peptide fused to a guide peptide, the latter binding to a protein of the target bacterium. This technology can eliminate the target bacterium selectively and specifically from the gut microbiota. The specificity of the targeting, being at the strain, species or genus level, depends on the sequence of the guide peptide used to provide the targeting. The treatment can be administered orally, such as by using an ingestible probiotic.
Type:
Application
Filed:
August 19, 2020
Publication date:
February 25, 2021
Applicant:
Baylor University
Inventors:
Christopher Michel Kearney, Ankan Choudhury, Patrick Ortiz
Abstract: A live virus composition that maintains infectivity and provides improved virus stability during one or more freeze/thaw cycles and/or during long term storage in a liquid state at temperatures ranging from just above freezing to ambient temperatures.
Type:
Application
Filed:
September 4, 2020
Publication date:
February 25, 2021
Inventors:
Jennifer R. LITOWSKI, Christine Claudia SISKA, Bruce Arthur KERWIN